Actively Recruiting

Phase 2
Age: 20Years - 85Years
FEMALE
NCT06839144

Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

Led by Tel-Aviv Sourasky Medical Center · Updated on 2025-07-11

60

Participants Needed

2

Research Sites

76 weeks

Total Duration

On this page

Sponsors

T

Tel-Aviv Sourasky Medical Center

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.

CONDITIONS

Official Title

Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

Who Can Participate

Age: 20Years - 85Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 20 to 85 years
  • ASA score 1 to 3 or ECOG Performance Status of 0 to 2
  • Suspected high-grade ovarian epithelial cancer based on imaging, clinical examination, CA125, and/or tumor biopsy
  • Planned primary or interval debulking surgery for ovarian cancer
  • Signed informed consent form
  • Willing and able to comply with study procedures physically and mentally
Not Eligible

You will not qualify if you...

  • Participation in another interventional study
  • Known allergy to study medications or related drug groups (non-steroidal anti-inflammatory drugs, beta-blockers)
  • Chronic treatment with beta-blockers or COX inhibitors except aspirin (which must be stopped 7 days before surgery and until 3 weeks post-surgery)
  • Current asthma or hospitalization/change in asthma treatment in past year
  • Active peptic disease
  • History of stroke or transient ischemic attack
  • Recent or concurrent malignancies except treated in-situ cervical carcinoma or basal-cell skin carcinoma
  • Renal failure with creatinine level over 1.5
  • Significant liver dysfunction (cirrhosis, bilirubin over 2)
  • Significant heart failure (NYHA class 3 or higher)
  • Bradycardia (heart rate 50 or less) or second/third-degree AV block
  • Right-sided heart failure due to pulmonary hypertension
  • Chronic digoxin treatment
  • Prinzmetal's angina
  • Significant cardiomegaly
  • Sick sinus syndrome
  • Peripheral vascular disease
  • Current unresected pheochromocytoma
  • Pregnancy
  • Immunosuppressive treatment exceeding 10 mg prednisone daily or other immunosuppressants within 7 days before trial drug
  • Immunodeficiency disorders

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

The Chaim Sheba Medical Center

Ramat Gan, Israel, 5266202

Actively Recruiting

2

Tel Aviv Sourasky Medical Center (Ichilov Hospital)

Tel Aviv, Israel, 6997801

Actively Recruiting

Loading map...

Research Team

S

Shamgar Ben-Eliyahu, Prof.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression | DecenTrialz